Vanguard Group
STOK icon

Vanguard Group’s Stoke Therapeutics STOK Stock Holding History

Vanguard Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$100M Sell
3,149,239
-14,635
-0.5% -$440K ﹤0.01% 1875
2025
Q3 		$74.4M Buy
3,163,874
+217,616
+7% +$3.73M ﹤0.01% 1976
2025
Q2 		$33.4M Buy
2,946,258
+162,056
+6% +$1.54M ﹤0.01% 2311
2025
Q1 		$18.5M Buy
2,784,202
+53,004
+2% +$494K ﹤0.01% 2539
2024
Q4 		$30.1M Sell
2,731,198
-28,049
-1% -$345K ﹤0.01% 2388
2024
Q3 		$33.9M Buy
2,759,247
+71,589
+3% +$1.01M ﹤0.01% 2348
2024
Q2 		$36.3M Buy
2,687,658
+972,104
+57% +$13.1M ﹤0.01% 2273
2024
Q1 		$23.2M Buy
1,715,554
+67,052
+4% +$406K ﹤0.01% 2530
2023
Q4 		$8.67M Buy
1,648,502
+17,814
+1% +$76.1K ﹤0.01% 3029
2023
Q3 		$6.42M Buy
1,630,688
+23,904
+1% +$157K ﹤0.01% 3141
2023
Q2 		$17.1M Buy
1,606,784
+474,797
+42% +$5.05M ﹤0.01% 2658
2023
Q1 		$9.43M Sell
1,131,987
-470,058
-29% -$4.24M ﹤0.01% 2964
2022
Q4 		$14.8M Sell
1,602,045
-445,859
-22% -$4.64M ﹤0.01% 2778
2022
Q3 		$26.3M Buy
2,047,904
+52,871
+3% +$843K ﹤0.01% 2512
2022
Q2 		$26.4M Buy
1,995,033
+55,643
+3% +$845K ﹤0.01% 2514
2022
Q1 		$40.8M Buy
1,939,390
+27,208
+1% +$545K ﹤0.01% 2403
2021
Q4 		$45.9M Buy
1,912,182
+64,567
+3% +$1.54M ﹤0.01% 2400
2021
Q3 		$47M Buy
1,847,615
+108,813
+6% +$3.03M ﹤0.01% 2399
2021
Q2 		$58.5M Buy
1,738,802
+77,791
+5% +$2.75M ﹤0.01% 2282
2021
Q1 		$64.5M Buy
1,661,011
+54,743
+3% +$3.12M ﹤0.01% 2170
2020
Q4 		$99.5M Buy
1,606,268
+300,308
+23% +$13.8M ﹤0.01% 1834
2020
Q3 		$43.7M Buy
1,305,960
+27,619
+2% +$789K ﹤0.01% 2084
2020
Q2 		$30.5M Buy
1,278,341
+482,351
+61% +$11.5M ﹤0.01% 2230
2020
Q1 		$18.2M Buy
795,990
+23,186
+3% +$573K ﹤0.01% 2338
2019
Q4 		$21.9M Buy
772,804
+99,220
+15% +$2.5M ﹤0.01% 2495
2019
Q3 		$14.5M Buy
673,584
+573,584
+574% +$16M ﹤0.01% 2629
2019
Q2 		$2.92M Buy
+100,000
New +$2.69M ﹤0.01% 3357

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group's STOK Position: Q4 2025 in Review

Vanguard Group reduced its Stoke Therapeutics (STOK) stake by 0.46% in Q4 2025, selling an estimated $440K and leaving 3,149,239 shares worth $100M. The position accounts for ﹤0.01% of the portfolio, ranked #1875.

Vanguard Group first reported a position in STOK in Q2 2019 and has held it in 27 quarters since. 183 funds tracked by Wall St. Rank hold STOK as of Q4 2025.

  • Vanguard Group held 3,149,239 shares of Stoke Therapeutics worth $100M as of Q4 2025.
  • Vanguard Group sold 14,635 Stoke Therapeutics shares in Q4 2025, an estimated $440K.
  • Stoke Therapeutics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1875 holding.
  • Vanguard Group first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • 183 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.